Tobira Therapeutics Inc  

(Public, NASDAQ:TBRA)   Watch this stock  
Find more results for Carol J. Cooper�
0.0000
0.0000 (0.00%)
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.44
Shares 10.98M
Beta     -
Inst. own 35%
Jan 20, 2015
Regado Biosciences and Tobira Therapeutics Merger Agreement Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -153.93% -234.93%
Return on average equity - -
Employees 11 -
CDP Score - -

Address

701 Gateway Blvd Ste 200
SOUTH SAN FRANCISCO, CA 94080-7041
United States - Map
+1-650-7416625 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Tobira Therapeutics, Inc. (Tobira) is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to treat liver disease, human immunodeficiency virus (HIV) fibrosis and inflammation. The Company�s product candidate, cenicriviroc (CVC,) is an immunomodulator that can be used to treat a number of disease states with high unmet medical need. CVC has been evaluated in a total of 16 completed Phase 1 and Phase 2 clinical trials in approximately 550 healthy volunteers and patients with HIV-1. The Company is developing CVC for non-alcoholic steatohepatitis (NASH). CVC is an oral, long-acting, once-daily, potent dual inhibitor, or antagonist, of chemokine receptor type 2 (CCR2), and type 5 (CCR5), with anti-inflammatory and anti-fibrotic activity. NASH is a severe type of non-alcoholic fatty liver disease (NAFLD).

Officers and directors

Laurent Fischer M.D. Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Christopher Peetz Chief Financial Officer
Age: 35
Bio & Compensation  - Reuters
Helen Jenkins Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Eric Lefebvre M.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Carol L. Brosgart M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Jeffrey H. Cooper CPA Independent Director
Age: 58
Bio & Compensation  - Reuters
Craig S. Gibbs Independent Director
Age: 51
Bio & Compensation  - Reuters
Patrick J. Heron Independent Director
Age: 43
Bio & Compensation  - Reuters
Gwen A. Melincoff Independent Director
Bio & Compensation  - Reuters